Bot Chart, page-6919

Agree with you Sarge.

SB seems a lot more convenient. The Phase 3 study for SB was also quite a bit larger.

SB is also proven in Japanese market, which gives a lot of confidence. Brella doesn't look like it's been on sale yet.

Brella has been known for same some time. I think approved in April this year by FDA? So I would say it's all been factored in by BOT and others.

Like you say, the hastle of having to go to a doc for treatment throughout the year would more of a hastle vs roll on.

Given SBs more robust Phase 3 trial than Brella's which gained approved, I would think that SB approval is almost a certainty.

As confident as ever, but funny how things can come up out that you can miss / don't think about.